Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

The Company believes that these next generation drug candidates fit synergistically with Telix’s therapeutics pipeline ... with international operations in the United States, Canada, Europe (Belgium ...

Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

Analysts expect United Therapeutics to post earnings of $6.54 per share and revenue of $734.74 million for the quarter. United Therapeutics Stock Up 2.2 % Shares of UTHR stock opened at $353.31 on ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. A biotechnology company in Research Triangle Park has taken a major step to develop a new option for ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has declined 7.4% over the past three months. However, a closer look at its sound ...

United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...